Par Pharm Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for PAR PHARM, and what generic alternatives to PAR PHARM drugs are available?
PAR PHARM has one hundred and forty-nine approved drugs.
There is one US patent protecting PAR PHARM drugs. There are thirteen tentative approvals on PAR PHARM drugs.
There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and eighty-one supplementary protection certificates in fifteen countries.
Summary for Par Pharm
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 95 |
| Ingredients: | 93 |
| NDAs: | 149 |
| Patent Litigation for Par Pharm: | See patent lawsuits for Par Pharm |
| PTAB Cases with Par Pharm as petitioner: | See PTAB cases with Par Pharm as petitioner |
Drugs and US Patents for Par Pharm
Expired US Patents for Par Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | 4,724,231 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
International Patents for Par Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006115626 | ⤷ Try a Trial |
| Australia | 2006240490 | ⤷ Try a Trial |
| South Korea | 20080000660 | ⤷ Try a Trial |
| European Patent Office | 1948613 | ⤷ Try a Trial |
| China | 101163679 | ⤷ Try a Trial |
| Japan | 2008538560 | ⤷ Try a Trial |
| Mexico | 2007013118 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Par Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2101777 | 2016C/032 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN EN COMBINAISON AVEC LE TADALAFIL; AUTHORISATION NUMBER AND DATE: EU/1/08/451 20151125 |
| 2330892 | SPC/GB17/001 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; REGISTERED: UK EU/1/15/1062 20151201; UK PLGB53487/0001 20151201 |
| 0237929 | SPC/GB97/088 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TOLCAPONE; REGISTERED: CH 54055/01 19970225; CH 54055/02 19970225; UK EU/1/97/044/001 19970827; UK EU/1/97/044/002 19970827; UK EU/1/97/044/003 19970827; UK EU/1/97/044/004 19970827; UK EU/1/97/044/005 19970827; UK EU/1/97/044/006 19970827 |
| 2101777 | 122016000039 | Germany | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120 |
| 1635783 | CA 2014 00016 | Denmark | ⤷ Try a Trial | PRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831 |
| 0240228 | C980022 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: QUETIAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER QUETIAPINEFUMARAAT; NAT. REGISTRATION NO/DATE: RVG 20826 - RVG 20828 19980427; FIRST REGISTRATION: GB PL 12619/0112 - PL 12619/0114 19970731 |
| 2330892 | 63/2016 | Austria | ⤷ Try a Trial | PRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REGISTRATION NO/DATE: EU/1/15/1062 (MITTEILUNG) 20151201 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
